MOONLAKE IMMUNOTHERAPEUTICS Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $300.00K.
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $1.10M.
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $900.00K, a 60.87% decline from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $2.30M.
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00.
- MOONLAKE IMMUNOTHERAPEUTICS share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|
| 2026-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.40M 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $900.00K 10-K · filed 2026-02-25 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $2.30M 10-K · filed 2026-02-25 | $2.26M 10-K · filed 2025-02-26 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |